

Medical Breast Training Program

Session Six: Malignant Breast Lesions	
<p>Course Description: In session six, you will learn about noninvasive and invasive breast cancer. You will become familiar with the different molecular subtypes of breast cancer and understand breast cancer staging. Not all breast cancer occurs in older women, therefore, we will help you become confident identifying rare presentations of breast cancer.</p>	
<p>Learning Objectives:</p> <ul style="list-style-type: none"> • Describe the difference between non-invasive and invasive breast cancer. • Identify rare types of breast cancer, including male breast cancer and pregnancy associated breast cancer. • Discuss breast cancer staging and the molecular subtypes of breast cancer. 	
30 Minutes	<p>Ductal Carcinoma In-Situ (<i>DCIS</i>) <i>Patricia A. Cronin, M.D.</i></p>
	<p>Objectives:</p> <ul style="list-style-type: none"> • Discuss the epidemiology, histopathology, grading, prognosis of ductal carcinoma in situ, and risk of recurrence. Explain why there is debate over DCIS as overdiagnosis? • Briefly outline local treatments for ductal carcinoma in situ. <ul style="list-style-type: none"> ○ Surgical (breast conservation sentinel node sampling not required vs mastectomy sentinel lymph node biopsy recommended) ○ Radiation • Summarize which patients with DCIS may benefit from endocrine therapy and discuss benefit of endocrine therapy in DCIS (recurrence vs survival benefit). What is the duration of endocrine therapy recommended for DCIS?
30 Minutes	<p>Invasive Ductal Carcinoma <i>Pooja Advani, M.B.B.S., M.D.</i></p>
	<p>Objectives:</p> <ul style="list-style-type: none"> • Discuss the epidemiology, histopathology, grading, and prognosis of invasive ductal carcinoma. • Review local and systemic treatment of early-stage invasive ductal breast carcinoma. <ul style="list-style-type: none"> ○ Surgical (breast conservation vs mastectomy with sentinel lymph node biopsy) ○ Systemic treatment (chemotherapy), immunotherapy, targeted HER2 treatment ○ Discuss the difference between neoadjuvant vs. adjuvant chemotherapy ○ Endocrine therapy for estrogen receptor positive cancers
30 Minutes	<p>Invasive Lobular Cancer <i>Megan Kruse, M.D.</i></p>
	<p>Objectives:</p> <ul style="list-style-type: none"> • Discuss the epidemiology, histopathology, and grading of invasive lobular carcinoma (ILC).

	<ul style="list-style-type: none"> • Describe prognosis and recurrence patterns of ILC • Address indications for breast MRI in the work-up of patients with newly diagnosed ILC. • <i>Briefly</i> review local and systemic treatment of early-stage invasive lobular breast carcinoma. <p>FYI THIS CONTENT BELOW WILL BE ADRESSED BY ANOTHER SPEAKER FOR IDC SO YOU CAN BE BRIEFF WHEN YOU DISCUSS:</p> <ul style="list-style-type: none"> -Surgical (lumpectomy w SLN biopsy vs mastectomy w SLN biopsy) -Systemic treatment (chemotherapy), immunotherapy, targeted HER2 treatment -Discuss the difference between neoadjuvant vs. adjuvant chemotherapy -Endocrine therapy for estrogen receptor positive cancers
30 Minutes	<p>Staging and Molecular Signatures <i>Megan Kruse, M.D.</i></p>
	<p>Objectives:</p> <ul style="list-style-type: none"> • Define breast cancer staging. • Review molecular subtypes of breast cancer. • Discuss the role of commercially available molecular profiling tests for cancer prognostication and therapy prediction (ex. Oncotype DX and Breast cancer Index).
30 Minutes	<p>Radiologic Correlates of Molecular Subtypes <i>Laura Dean, M.D.</i></p>
	<p>Objectives:</p> <ul style="list-style-type: none"> • Describe the four main molecular subtypes of breast cancer • Review imaging examples of each subtype • Discuss how determination of molecular subtype has clinical implications for treatment of breast cancer • Understand the role of immunohistochemistry (IHC) testing for newly diagnosed breast cancers • Integration of molecular subtype into determination of clinical staging and its role in counseling patient outcomes
30 Minutes	<p>Rare Breast Malignancies <i>Zahraa AlHilli, M.D.</i></p>
	<p>Objectives:</p> <ul style="list-style-type: none"> • Discuss the epidemiology, clinical presentation, histopathology, and prognosis of Paget’s Disease of the Breast. • Discuss the epidemiology, clinical presentation, histopathology, and prognosis of inflammatory breast cancer. • OPTIONAL → Briefly highlight rare forms of invasive ductal carcinoma: medullary, mucinous, papillary, and tubular
30 Minutes	<p>Fertility Preservation <i>Elizabeth (Ebbie) A. Stewart, M.D.</i></p>
	<p>Objectives:</p> <ul style="list-style-type: none"> • Review common methods of preserving fertility at the time of diagnosis. • Outline timing considerations of fertility preservation at diagnosis and the safety of treatment delays.

	<ul style="list-style-type: none"> • Discuss the success rate for pregnancy after fertility preservation and safety considerations of pregnancy after a breast cancer diagnosis.
30 Minutes	<p>Male Breast Issues <i>Patricia A. Cronin, M.D.</i></p>
	<p>Objectives:</p> <ul style="list-style-type: none"> • Review the clinical presentation, evaluation, and management of gynecomastia. • List risk factors for male breast cancer. • Discuss epidemiology, clinical presentation, histopathology, and prognosis of male breast cancer.
30 Minutes	<p>Pregnancy Associated Breast Cancer <i>Kathryn J. Ruddy, M.D.</i></p>
	<p>Objectives:</p> <ul style="list-style-type: none"> • Define pregnancy-associated breast cancer. • Discuss the prognosis of pregnancy-associated breast cancer. • Briefly review treatment dilemmas for pregnancy associated breast cancer.
<p>Livestream June 25, 2022 9:00 a.m. – 12:00 p.m. CT</p>	<p>Benign & Malignant Breast Lesions Case Discussions (5) Sandhya Pruthi, M.D., <i>Melinda Wu, M.D.</i>, <i>Asha A. Bhatt, M.D.</i>, <i>Zahraa AlHilli, M.D.</i>, <i>Megan Kruse, M.D.</i>, <i>Charles D. Sturgis, M.D.</i></p>